Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

(2019) Joseph Mikhael et al.   BLOOD

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

(2019) Michel Attal et al.   LANCET

Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma

(2018) Serena Rocchi et al.   HAEMATOLOGICA

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

(2018) Meletios Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma

(2018) Serena Rocchi et al.   HAEMATOLOGICA

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

(2018) Meletios Dimopoulos et al.   BLOOD

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis

(2016) Meletios A. Dimopoulos et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

(2016) Jesus Berdeja et al.   Clinical Lymphoma Myeloma & Leukemia

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

(2016) K. C. Weisel et al.   HAEMATOLOGICA

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

(2016) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

(2016) K. C. Weisel et al.   HAEMATOLOGICA

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

(2015) P. Moreau et al.   HAEMATOLOGICA

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

(2015) P. Moreau et al.   HAEMATOLOGICA

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

(2014) M A Dimopoulos et al.   LEUKEMIA

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

(2013) C. Scheid et al.   HAEMATOLOGICA

Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics

(2012) Bernd Meibohm et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

(2010) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study

(2009) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

(2008) J F San-Miguel et al.   LEUKEMIA